Genomics-Driven Precision Medicine in Pediatric Solid Tumors
Praewa Suthapot, Wararat Chiangjong, Parunya Chaiyawat, Pongsakorn Choochuen, Dumnoensun Pruksakorn, Surasak Sangkhathat, Suradej Hongeng, Usanarat Anurathapan, Somchai Chutipongtanate
Abstract
Over the past decades, several study programs have conducted genetic testing in cancer patients to identify potential genetic targets for the development of precision therapeutic strategies. These biomarker-driven trials have demonstrated improved clinical outcomes and progression-free survival rates in various types of cancers, especially for adult malignancies. However, similar progress in pediatric cancers has been slow due to their distinguished mutation profiles compared to adults and the low frequency of recurrent genomic alterations. Recently, increased efforts to develop precision medicine for childhood malignancies have led to the identification of genomic alterations and transcriptomic profiles of pediatric patients which presents promising opportunities to study rare and difficult-to-access neoplasms. This review summarizes the current state of known and potential genetic markers for pediatric solid tumors and provides perspectives on precise therapeutic strategies that warrant further investigations.